View Cancer Clinical Trials

Cancer Answer Line: 866.223.8100

Cancer Answer Line:

866.223.8100

View Cancer Clinical Trials

ABTC 1202   |   13-927
Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma

Disease(s)
Brain
Glioblastoma
Hospital(s)
Main Campus
Phase(s)
Phase 1
Stage(s)
Type(s)
Drug(s)
Temozolomide (SCH 52365)

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description
Primary
  1. The primary objective of the Phase I portion of the clinical trial is to determine the maximum tolerated doses (MTD) of MK-1775 in combination with the current standard of care (radiotherapy/temozolomide for concomitant therapy and temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.
  2. To define the MTD of MK-1775 in combination with 6 weeks of daily (M-F) radiotherapy (RT) and concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly diagnosed glioblastoma (Arm 1)
  3. To define the MTD of MK-1775 in combination with adjuvant TMZ administered at 150 mg/m^2/day-200 mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ (Arm 2)
Secondary
  1. To characterize the safety profile of MK-1775 in combination with RT and concomitant TMZ (Arm 1) and MK-1775 with adjuvant TMZ (Arm 2) in patients with newly diagnosed glioblastoma
  2. To assess the pharmacokinetic (PK) profile of MK-1775 in combination with upfront radiation/TMZ and adjuvant TMZ in patients with newly diagnosed glioblastoma
Intratumoral Correlatives/Pharmacokinetics Objectives
  1. To determine the intratumoral concentration of MK-1775 achieved in patients treated with the putative MTD
  2. To characterize the time course of MK-1775 in extracellular fluid within brain tumors following a single oral dose of drug by microdialysis
  3. To characterize MGMT methylation and P53 pathway status, also P-gp and weel expression levels in patients with newly diagnosed glioblastoma treated with standard therapy in combination with MK-1775

Inclusion Criteria
  1. Patients must be 18 years of age or older.
  2. Patients must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist. (See Section 9.5.4)
  3. Patients must have a Karnofsky Performance Status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
  4. Patients must have the following organ and marrow function:
    1. Absolute neutrophil count ≥ 1,500/mcL
    2. Platelets ≥ 100,000/mcL
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin within normal institutional limits
    5. AST (SGOT)/ALT (SGPT) ≤ 3 � institutional upper limit of normal
    6. Creatinine within normal institutional limits OR
    7. Creatinine clearance ≥ 60 ml/min/1.73m^2 for patients with creatinine levels above institutional normal
    8. APTT ≤ 1.5 x institutional upper limit of normal
  5. Patients must be able to provide written informed consent.
  6. Patients must have MRI within 21 days of starting treatment.
  7. Women of childbearing potential must have a negative serum pregnancy test prior to study entry. Women of childbearing potential and men must agree to use two birth control methods (either two barrier methods or a barrier method plus a hormonal method) or abstinence prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  8. Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with prior malignancies must be disease-free for ≥ five years.
  9. Patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatment.
  10. Patients must be able to swallow whole capsules.
Phase I Patients
  1. Phase I patients must have histologically proven glioblastoma.
  2. Phase I patients must have recovered from the immediate post-operative period.
  3. Phase I patients going on Arm 1 or Combination Dose Cohort must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor. Glucocorticoid therapy is allowed.
  4. Phase I patients going on Arm 2 must have received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study. Patients must have received at least 80% of planned temozolomide and radiation therapy with no grade 3 or grade 4 toxicity attributed to the temozolomide. Arm 2 patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor. Prior Gliadel Wafers are allowed. Glucocorticoid therapy is allowed.
Intratumoral Drug Distribution Study Patients
  1. Intratumoral Drug Distribution patients must have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy.
  2. Intratumoral Drug Distribution patients must be undergoing repeat surgery that is clinically indicated as determined by their care providers.
  3. Intratumoral Drug Distribution patients must have measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment. Patient must be able to tolerate MRIs.
  4. Intratumoral Drug Distribution patients may have an unlimited number of prior therapy regimens.
  5. Intratumoral Drug Distribution patients must have recovered from severe toxicity of prior therapy. The following intervals from previous treatments are required to be eligible:
    1. 12 weeks from the completion of radiation
    2. 6 weeks from a nitrosourea chemotherapy
    3. 3 weeks from a non-nitrosourea chemotherapy
    4. 4 weeks from any investigational (not FDA-approved) agents
    5. 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., tarceva, hydroxychloroquine, bevacizumab, etc.)

Exclusion Criteria
  1. Patients receiving any other investigational agents are ineligible.
  2. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or MK-1775 are ineligible. The MK-1775 Investigator Brochure and the temozolomide package insert can be referenced for more information.
  3. Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol. Patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs. Patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of MK-1775.
  4. Patients may not be on drugs known to be moderate or potent inhibitors/inducers of CYP3A4, sensitive substrates of CYP3A4, or substrates of CYP3A4 with narrow therapeutic windows (see Section 4.6, Prohibited Medication During Study).
  5. Patients may not be on anti-coagulants (warfarin, etc.) other than low-molecular weight heparin (LMWH).
  6. Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible.
  7. Pregnant women are excluded from this study because MK-1775 has potential for teratogenic or abortifacients effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-1775, breastfeeding should be discontinued if the mother is treated with MK-1775.
  8. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MK-1775. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.

Cleveland Clinic Mobile Site